Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Urinary Bladder Neoplasms 5Melanoma 2Glioblastoma 2Brain Neoplasms 2Urothelial Carcinoma of the Bladder 1Squamous Cell Carcinoma of Head and Neck 1Oligodendroglioma 1Non-Muscle Invasive Bladder Urothelial Carcinoma 1Non-Muscle Invasive Bladder Neoplasms 1Neuroblastoma 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Lymphoma, Follicular 1Laryngeal Neoplasms 1Glioma 1Ganglioneuroblastoma 1Craniopharyngioma 1Carcinoma 1Astrocytoma 1

Interventions

Cyclophosphamide 13Temozolomide 10Magnetic Resonance Spectroscopy 10dinutuximab 8X-Rays 8Specimen Handling 8Irinotecan 8Biopsy 8Phantoms, Imaging 7Topotecan 6Nuclear Medicine Department, Hospital 6fludarabine 5Vincristine 53-Iodobenzylguanidine 5fludarabine phosphate 4Granulocyte-Macrophage Colony-Stimulating Factor 4Etoposide 4tipifarnib 3sargramostim 3Radiotherapy 3Melphalan 3Isotretinoin 3Filgrastim 3Doxorubicin 3Carboplatin 3ulixertinib 2tazemetostat 2selpercatinib 2saponin QA-21V1 2pembrolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × Transurethral Resection of Bladder × 90 days × Clear all
NCT06172296 2026-06-03

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 3 Recruiting
478 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡